- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04713982
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
December 12, 2023 updated by: Amy E Brown, Vanderbilt University Medical Center
Examine the effects of deutetrabenazine on functional speech and gait impairment
Study Overview
Detailed Description
This is a two-year, prospective, single-arm study examining the effects of deutetrabenazine on functional speech and gait impairment.
Participants will undergo comprehensive evaluations of speech production, fine motor skills, gait, and balance both before and after the initiation of deutetrabenazine.
The investigators will utilize a variety of standardized, well-validated assessments as well as 3D motion analysis of both speech and gait parameters to determine the functional impact of deutetrabenazine on speech and motor performance.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Amy E Brown, MD
- Phone Number: 615.936.0060
- Email: amy.brown@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt University Medical Center
-
Contact:
- Amy E Brown, MD
- Phone Number: 615-936-0060
- Email: amy.brown@vumc.org
-
Principal Investigator:
- Amy E Brown, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of HD with documented CAG repeat ≥ 37
- UHDRS total maximal chorea score of ≥ 8
- Able to walk at least 10 meters
- Medically stable outpatient, based on the investigator's judgment
- Willing and able to give written informed consent prior to performing any study procedures
- Have completed at least 10th grade
- Montreal Cognitive Assessment score ≥ 22 on screening
- Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion
Exclusion Criteria:
- Severe depression or suicidal ideation
- History of suicidal behavior
- Unstable or serious medical or psychiatric illness
- Renal or hepatic impairment
- Severe speech impairment or anarthria
- Inability to swallow study medication
- Women who are pregnant or breast feeding
- History of alcohol or substance abuse within the last 12 months
- Current use of VMAT2 inhibitor (tetrabenazine, deutetrabenazine, valbenazine)
- Concurrent participation in any other investigational drug trials
- EKG QTcF> 500 mse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deutetrabenazine
The mode of administration is oral.
Subjects will be started on deutetrabenazine at a dose of 6mg/day.
Dosing will be up-titrated in increments of 6mg/day per week to achieve optimal chorea control.
|
Maximum dose of 48mg/day or up to 36 mg/d if receiving a strong CYP2D6 inhibitor
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sentence Intelligibility Test (SIT)
Time Frame: Up to 10 weeks
|
SIT is a measure of speech intelligibility that requires the participant to read aloud 11 sentences that increase in length from 5 to 10 words.
Speech intelligibility is indexed in terms of percent intelligible.
This is determined by calculating the mean number of correct words transcribed from the SIT transcriptions by three unfamiliar listeners and dividing this by the total number of words in the 11-sentence sample.
|
Up to 10 weeks
|
Motor Speech Evaluation (MSE)
Time Frame: Up to 10 weeks
|
The MSE will include a set of tasks described by Duffy (2013) that permit consistent rating of perceptual characteristics associated with motor speech disorders.
These tasks include vowel prolongation, alternating motion rates, sequential motion rates, and contextual speech (oral reading, picture description, conversational speech).
These recordings will be used to complete the perceptual assessment of speech characteristics using the Mayo Clinic classification system.
|
Up to 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
3-D optical motion capture system recording
Time Frame: Up to 10 weeks
|
To determine the effect of deutetrabenazine on facial movements at rest and during functional task performance (e.g., speaking, chewing) in individuals with HD, the investigators will utilize a 3-D optical motion capture system (Motion Analysis, Ltd.) consisting of six infrared Kestrel cameras with a sensor resolution of 2.2 million pixels at 2,048 x 1,088 full resolution.
Facial movements will be captured by placing small (2mm) reflective spheres on each patient's jaw (right/left/center), mouth (right/left corner, upper/lower lip center), and cheeks (right/left zygomatic bone).
Further, reflective markers will be placed on the forehead (right/left eyebrows, right/left forehead).
Four head markers will serve as reference markers for head movement correction and transposition of all marker movement into a head-based coordinate system.
|
Up to 10 weeks
|
Functional Joint Kinematics Improvements
Time Frame: Up to 10 weeks
|
To determine the effect of deutetrabenazine on joint kinematics and spatiotemporal parameters using 3D motion analysis.
Participants will be recording using the Xsens MVN Awinda motion capture system during a 10 meter walk test.
Lower- and upper-limb kinematics will be recorded.
Wireless sensors will be placed on the ankle, thigh, hand, forearm, bicep, and head.
The velocity of the 10 meter walk can be compared to age and gender matched normative values.
Gait speed correlates with functional ability, balance and confidence.
Three trials are completed, and the average of the three scores is documented.
This test will be completed using the 3D motion analysis system.
|
Up to 10 weeks
|
Four Square Step Test (FSST)
Time Frame: Up to 10 Weeks
|
The FSST assesses dynamic balance stepping over objects forward, backwards, and sideways.
The individual is required to step as fast as possible into each square, requiring the individual to step objects in varying directions.
Two tests are completed, with the best time documented as the score.
|
Up to 10 Weeks
|
Functional Gait Assessment (FGA)
Time Frame: Up to 10 weeks
|
The FGA assesses dynamic balance during gait and provides objective information regarding risk of falling.
The FGA consists of ten items scored from 0-3, with a maximum total score of 30 points.
Items include normal walking, walking with speed changes, walking with head turns, pivot turns, obstacle negotiation, tandem walking, walking with eyes closed, walking backward, and negotiating stairs.
Scores less than 23/30 are predictive of falls.
|
Up to 10 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Communication Effectiveness Survey
Time Frame: Up to 10 weeks
|
The CES is an 8-item patient reported outcome measure that is designed to rate communication effectiveness in individuals with dysarthria.
Each of the items presents a communication situation (e.g., talking on the phone with a familiar listener; talking while driving in a car, etc.) and the participant rates his or her perceived ability to communicate in that situation on a scale from "1" (not at all effective) to "4" (very effective).
|
Up to 10 weeks
|
Nine-Hole Peg Test
Time Frame: Up to 10 weeks
|
The Nine-Hole Peg Test is an assessment of fine motor coordination that measures each hand individually.
The final score reported is the time required to place and remove nine pegs with each hand.
Results are compared to age and gender matched normative values.
This test will assess the impact of chorea on fine motor movements and dexterity.
|
Up to 10 weeks
|
10 Meter Walk test
Time Frame: Up to 10 Weeks
|
With the 10 Meter Walk Test, velocity can be compared to age and gender matched normative values.
Gait speed correlates with functional ability, balance and confidence.
Three trials are completed, and the average of the three scores is documented.
This test will be completed using the 3D motion analysis system.
|
Up to 10 Weeks
|
Health Status
Time Frame: Up to 10 weeks
|
The investigators will be using the short-form 36 (SF-36) which is a generic patient-reported outcome measure that quantifies perceived health status.
It is used as a measure of health-related quality of life.
Sub sections include physical function, role limitations secondary to physical problems, general health perceptions, vitality, social functioning, role limitations due to emotional problems, mental health, and health transition.
Participants respond referring to their perceived health over the past 4 weeks.
|
Up to 10 weeks
|
The Functional Assessment of Chronic Illness Therapy (FACIT) scale
Time Frame: Up to 10 weeks
|
The FACIT scale has been validated in a number of chronic conditions, including cancer, Parkinson's disease, multiple sclerosis, and HIV/AIDS (Webster 2003).
It includes assessments of physical, social, emotional, and functional well-being and is available in multiple condition- and treatment-specific versions.
The FACIT scale is sensitive to changes in individual participants over time and can also be used to compare patient populations.
|
Up to 10 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Amy E Brown, MD, Vanderbilt University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 19, 2021
Primary Completion (Estimated)
August 30, 2024
Study Completion (Estimated)
April 1, 2025
Study Registration Dates
First Submitted
January 6, 2021
First Submitted That Met QC Criteria
January 13, 2021
First Posted (Actual)
January 19, 2021
Study Record Updates
Last Update Posted (Estimated)
December 13, 2023
Last Update Submitted That Met QC Criteria
December 12, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Heredodegenerative Disorders, Nervous System
- Dementia
- Cognition Disorders
- Chorea
- Huntington Disease
Other Study ID Numbers
- 200069
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Huntington Disease
-
University of IowaThe University of Texas Health Science Center, Houston; Children's Hospital... and other collaboratorsRecruitingJuvenile Huntington Disease | Juvenile-Onset Huntington DiseaseUnited States
-
Sanguine BiosciencesHoffmann-La RocheRecruitingHuntington Disease | Huntington's Dementia | Huntington Disease, Late Onset | Huntington; Dementia (Etiology)United States
-
PrileniaCompletedHealth Volunteers, Huntington DiseaseGermany
-
Assistance Publique - Hôpitaux de ParisCEACompletedBrain Neuroimaging Biomarkers in Huntington DiseaseFrance
-
European Huntington's Disease NetworkCompletedHuntington Disease, JuvenileGermany, United Kingdom
-
Novartis PharmaceuticalsCompletedEarly Manifest Huntington DiseaseCanada, Germany, France, Spain, Hungary
-
University Hospital, AngersCompletedPresymptomatic Huntington DiseaseFrance
-
SOM Innovation Biotech SAActive, not recruitingHuntington ChoreaSpain, Germany, Italy, United Kingdom, France, Poland, Switzerland
-
Neurocrine BiosciencesEnrolling by invitation
-
Neurocrine BiosciencesHuntington Study GroupActive, not recruitingChorea, HuntingtonUnited States, Canada
Clinical Trials on Deutetrabenazine
-
University of PennsylvaniaTeva Branded Pharmaceutical Products R&D, Inc.Active, not recruiting
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedCerebral Palsy, DyskineticUnited States, Denmark, Israel, Italy, Poland, Russian Federation, Spain, Ukraine, United Kingdom, Canada, Slovakia, Belgium
-
Teva Branded Pharmaceutical Products R&D, Inc.Nuvelution TS Pharma, Inc.CompletedTourette SyndromeUnited States, Canada, Denmark, Russian Federation, Serbia, Spain
-
Teva Branded Pharmaceutical Products R&D, Inc.Nuvelution TS Pharma, Inc.CompletedTourette SyndromeUnited States, Argentina, Australia, Colombia, Hungary, Italy, Korea, Republic of, Mexico, Poland, Ukraine
-
Auspex Pharmaceuticals, Inc.CompletedChorea Associated With Huntington DiseaseUnited States, Australia, Canada
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedCerebral Palsy, DyskineticUnited States, Italy, Russian Federation, Spain, Denmark, Israel, Poland, Ukraine, United Kingdom
-
Auspex Pharmaceuticals, Inc.CompletedTardive DyskinesiaUnited States, Czechia, Germany, Hungary, Poland, Slovakia
-
Teva Branded Pharmaceutical Products R&D, Inc.Nuvelution TS Pharma, Inc.TerminatedTourette SyndromeUnited States, Argentina, Australia, Canada, Colombia, Denmark, Hungary, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Serbia, Spain, Ukraine
-
Auspex Pharmaceuticals, Inc.CompletedTardive DyskinesiaUnited States, Poland, Czechia, Slovakia
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed